{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["34(6)"],"submitter":["Haq AU"],"pubmed_abstract":["

Objectives: This meta-analysis compared the efficacy and safety of drug-coated balloon (DCB) angioplasty with drug-eluting stent (DES) for the treatment of de novo coronary artery disease.

Methods

Following PRISMA guidelines, we conducted a systematic search of major databases, including Cochrane, Medline, Embase and ClinicalTrials.gov, to identify eligible randomized controlled trials (RCTs) comparing DCB and DES. Mantel-Haenszel model was used for dichotomous outcomes. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model using RevMan software.

Results

Thirteen RCTs with a total of 4,686 patients were included. The analysis found no significant differences between DCB and DES for all-cause mortality (RR: 1.11, 95% CI: 0.81-1.5"],"journal":["Medical principles and practice : international journal of the Kuwait University, Health Science Centre"],"pagination":["544-554"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12303576"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of Drug-Coated Balloon versus Drug-Eluting Stent for Patients with De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis."],"pmcid":["PMC12303576"],"pubmed_authors":["Yousaf H","Suhail A","Nadeem B","Bungish MK","Shahid MA","Rehman MEU","Ahmed R","Alsubari AAAMA","Ahmad A","Nawal A","Wazir HU","Haq AU","Maqbool H","Hassan H","Ahmad Cheema H","Khan MA","Ahsan W"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of Drug-Coated Balloon versus Drug-Eluting Stent for Patients with De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis.","description":"

Objectives: This meta-analysis compared the efficacy and safety of drug-coated balloon (DCB) angioplasty with drug-eluting stent (DES) for the treatment of de novo coronary artery disease.

Methods

Following PRISMA guidelines, we conducted a systematic search of major databases, including Cochrane, Medline, Embase and ClinicalTrials.gov, to identify eligible randomized controlled trials (RCTs) comparing DCB and DES. Mantel-Haenszel model was used for dichotomous outcomes. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model using RevMan software.

Results

Thirteen RCTs with a total of 4,686 patients were included. The analysis found no significant differences between DCB and DES for all-cause mortality (RR: 1.11, 95% CI: 0.81-1.5","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-06T16:54:06.724Z","creation":"2025-08-27T03:10:15.698Z"},"accession":"S-EPMC12303576","cross_references":{"pubmed":["40582348"],"doi":["10.1159/000547099"]}}